Lupitros Eye Drop contains Travoprost 0.004% w/v, a prostaglandin analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Travoprost acts by increasing the outflow of aqueous humor through the uveoscleral pathway, thereby effectively lowering IOP. This medication is typically administered once daily in the affected eye(s), preferably in the evening, to optimize therapeutic outcomes. Lupitros Eye Drop has demonstrated efficacy in reducing IOP, which is critical in preventing optic nerve damage and subsequent vision loss associated with glaucoma. Common adverse effects may include ocular hyperemia, eyelash growth, eye irritation, and increased pigmentation of the iris or periocular skin. Patients should be advised to avoid contamination of the dropper tip and to remove contact lenses prior to administration, reinserting them after 15 minutes. Caution is warranted in patients with a history of intraocular inflammation or macular edema. Lupitros Eye Drop should be used under the supervision of an ophthalmologist, with regular monitoring of intraocular pressure and ocular health to ensure safety and efficacy. It is contraindicated in patients with hypersensitivity to travoprost or any component of the formulation.